Trials / Completed
CompletedNCT00037570
Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage
A Randomized Study of the Effect of Intravenous Pantoprazole on Gastric pH After Successful Hemostasis in Patients With Bleeding Peptic Ulcer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, parallel-group, dose-ranging, comparator-controlled study of the effect of pantoprazole on intragastric pH after successful endoscopic hemostasis in hospitalized patients. Patients will receive either intravenous pantoprazole (one of two regimens) or ranitidine (the comparator) within 2 hours of successful hemostasis and administration will continue for 72 hours after hemostasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pantoprazole |
Timeline
- Start date
- 2000-11-01
- Primary completion
- 2002-02-01
- Completion
- 2002-02-01
- First posted
- 2002-05-20
- Last updated
- 2013-02-08
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00037570. Inclusion in this directory is not an endorsement.